Director Rahul D. Ballal receives 17,126 ELVN stock options in Form 4

Rhea-AI Filing Summary

Ballal Rahul D. reported acquisition or exercise transactions in this Form 4 filing.

Enliven Therapeutics, Inc. reported that director Rahul D. Ballal received a grant of 17,126 stock options. The transaction is coded as a grant or award and recorded with a transaction price of $0.00 per option.

According to the vesting terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as Ballal continues serving as a non-employee director through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ballal Rahul D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,126	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 17,126 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ballal Rahul D.

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		17,126		(1)	02/12/2036	Common Stock	17,126	$0	17,126	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enliven Therapeutics (ELVN) report for Rahul D. Ballal?

Enliven Therapeutics reported a grant of 17,126 stock options to director Rahul D. Ballal. The Form 4 classifies this as a grant or award acquisition, with a recorded transaction price of $0.00 per option and all options held directly after the transaction.

How many Enliven Therapeutics (ELVN) stock options were granted in this Form 4?

The Form 4 shows a grant of 17,126 stock options to director Rahul D. Ballal. Following the transaction, he directly holds all 17,126 derivative securities reported, reflecting this single award rather than multiple separate option grants.

What are the vesting terms for Rahul D. Ballal’s ELVN stock option grant?

All 17,126 options will vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, provided Ballal continues as a non-employee director through the applicable vesting date.

Is the ELVN stock option grant to Rahul D. Ballal a purchase or a grant?

The transaction is explicitly categorized as a grant or award acquisition, not an open-market purchase. It is coded as transaction type “A” for grant, award, or other acquisition, with no buy or sell transactions reported in this Form 4 filing.

Does the Enliven Therapeutics Form 4 show any stock sales by Rahul D. Ballal?

No stock sales are reported in this Form 4. The transaction summary lists one acquisition transaction and zero dispositions, buys, or sells, indicating this filing only records the stock option grant to Rahul D. Ballal, not any share sales.